PCN63 - Cost Per Responder Analysis from the Checkmate 025 Phase III Trial of Nivolumab Versus Everolimus in Previously Treated Patients with Advanced Renal Cell Carcinoma.
Saved in:
| Title: | PCN63 - Cost Per Responder Analysis from the Checkmate 025 Phase III Trial of Nivolumab Versus Everolimus in Previously Treated Patients with Advanced Renal Cell Carcinoma. |
|---|---|
| Authors: | Liu, JS1, Bell, J2, Sumati, R2 |
| Source: | Value in Health. May2016, Vol. 19 Issue 3, pA145-A145. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 10983015 |
|---|---|
| DOI: | 10.1016/j.jval.2016.03.1562 |
